OBIO is proud to announce its 2018 Capital Access Advisory Program (CAAP®) and the 12 high-potential health science companies in this year’s cohort. Now in its sixth year, this year’s OBIO CAAP companies will work with OBIO and a vast network of expert advisors over the next year to achieve key goals and objectives which will position them for successful financing. OBIO CAAP companies are advancing and accelerating the development and commercialization of therapeutics, diagnostics, medical devices and digital health products and services to benefit Ontario and global human health.
2018 OBIO CAAP Companies
Adapsyn Bioscience has developed a bioinformatics platform that uses machine learning and microbial genomic and metabolomic data to identify novel natural products that can be developed as biomarkers or therapeutics.
Braze Mobility offers an after-market product for powered wheelchairs that increases safety by preventing collisions and offering feedback to the driver, while maximizing driver autonomy and freedom.
Bright Angel Therapeutics is developing a novel antifungal drug platform that targets antifungal drug resistance to transform existing antifungals from ineffective to highly efficacious against all leading fungal pathogens.
Elucid is building the world’s first AI dermatology assistant (AIDA™) system as clinical decision support for early detection and non-invasive diagnosis of skin cancer and skin diseases.
HelpWear has developed HeartWatch, a clinical grade contactless ECG monitor that will contact EMS after detecting heart attacks.
LifeShield has developed a transparent antibacterial adhesive film for touch screens in hospitals and other settings which inhibits the spread of infections.
MDDT has developed TremorTek, a theranostic device to guide neurologists in treating Parkinson tremors using botulinum toxin.
MediSeen is a home health care practice management platform that enables physicians and allied care providers to grow their house call practice.
Ontario based Next Healthcare Technologies has built CareCDS, a real-time information gathering platform for healthcare and pharma industry.
Polumiros has developed ReFilx, a polymeric filler that provides breast cancer patients a cosmetically superior and minimally-invasive solution for the restoration of tissue defects following lumpectomy.
Rna Diagnostics is transforming cancer treatment with their RNA Disruption Assay, a treatment response monitoring technology that allows oncologist to know early on if cancer treatment is efficacious or should be stopped.
Steadiwear has created a lightweight battery-free glove, called Steadiglove, that reduces hand tremors in Essential Tremor and Parkinson’s Disease allowing patients to do their daily activities with less frustration and more independence.